Zobrazeno 1 - 10
of 892
pro vyhledávání: '"5 Alpha-Reductase Inhibitor"'
Autor:
Gian Maria Busetto, Francesco Del Giudice, Daniele D'Agostino, Daniele Romagnoli, Andrea Minervini, Bernardo Rocco, Alessandro Antonelli, Antonio Celia, Riccardo Schiavina, Luca Cindolo, Benjamin I. Chung, Jae Heon Kim, Martina Maggi, Alessandro Sciarra, Ettore De Berardinis, Angelo Porreca
Publikováno v:
Archivio Italiano di Urologia e Andrologia, Vol 91, Iss 4 (2020)
Background: Combination therapy with 5 alpha-reductase inhibitor (5-ARI) and alpha-blocker can be considered as a gold standard intervention for medical management of lower urinary tract symptoms related to benign prostatic hyperplasia (LUTS/BPH). On
Externí odkaz:
https://doaj.org/article/1100407fbb4248c2a5fafd6edc93b8e3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America, 1996 Oct . 93(21), 11802-11807.
Externí odkaz:
https://www.jstor.org/stable/40517
Publikováno v:
Medicina, Vol 57, Iss 4, p 368 (2021)
Background and objectives: Treatment of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH) has shifted over the last decades, with medical therapy becoming the primary treatment modality while surgery is being reserved
Externí odkaz:
https://doaj.org/article/91eff247e9d94fcc881d02902a0234fa
Autor:
Zongwei Wang, Ra'ad Al-Faouri, Leo L. Tsai, Xingbo Long, Christina Sharkey, Boris Gershman, Aria F. Olumi
Publikováno v:
Journal of Urology. 207:876-884
As men age, the prostate continues to grow on average 2.5% per year. While the variable growth rate of the total prostate gland is recognized, the growth rate of different prostate zones remains largely unclear. We evaluated the growth patterns of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba98ca25000d9a697d2bd703dc1defdc
https://doi.org/10.1097/ju.0000000000002332
https://doi.org/10.1097/ju.0000000000002332
Autor:
Rogelio Valdez, Andrei S. Purysko, Ethna Auschof, Eric A. Klein, Giuseppe D'Ippolito, Jennifer Bullen
Publikováno v:
Journal of Urology. 206:1139-1146
We evaluated the influence of 5-alpha reductase inhibitors (5-ARIs) on the performance of magnetic resonance imaging (MRI) for detection of Gleason grade group (GG) ≥2 prostate cancer, and on apparent diffusion coefficient (ADC) maps.This single ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::269ac7852c93b21609b484224a96d705
https://doi.org/10.1097/ju.0000000000001932
https://doi.org/10.1097/ju.0000000000001932
Autor:
James T. Kearns, Jason Zhu, Stephen B. Riggs, Kris E. Gaston, Timothy Hetherington, Claud Grigg, Earle F. Burgess, William E. Anderson, Justin T. Matulay, Peter E. Clark
Publikováno v:
Urology Practice. 8:619-623
Introduction:5-Alpha reductase inhibitor (5-ARI) use leads to a 50% decline in serum prostate specific antigen (PSA) without a concomitant decrease in prostate cancer (PCa) risk. We hypothe...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8df786099986a96516d235e848fe9ce8
https://doi.org/10.1097/upj.0000000000000257
https://doi.org/10.1097/upj.0000000000000257
Autor:
Samuel Ohlander, Danielle Velez
Publikováno v:
Fertility and Sterility. 116:618-624
Primum non nocere. As physicians, our goal is to treat illnesses and alleviate suffering; however, in doing so, we can generate new problems in a game of medical whack-a-mole. For some patients, certain consequences or side effects are tolerable, whi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68459974a8341a313d5daa47d2581224
https://doi.org/10.1016/j.fertnstert.2021.07.1202
https://doi.org/10.1016/j.fertnstert.2021.07.1202
Autor:
Luca Gallelli, Andrea Scardigli, Lucia Muraca, Alessandro Casarella, Tommaso Cai, Giovambattista De Sarro, Davida Mirra, Irene Tamanini, Manuela Colosimo, Gianmarco Marcianò, Antonio La Torre, Vincenzo Rania, Caterina Palleria
Publikováno v:
Uro, Vol 1, Iss 12, Pp 82-98 (2021)
This is a critical review of the current literature data about sexual dysfunction as a potential side effect related to drugs commonly used for the treatment of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms. In this narrative review,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ab51da6b5188145980b08ab385a082e
https://doi.org/10.3390/uro1030012
https://doi.org/10.3390/uro1030012
Publikováno v:
International Journal of Ayurvedic Medicine. 12:427-430
Benign Prostatic Hyperplasia is a common senile disease. The present modern conservative management includes use of alpha blockers and 5 alpha reductase inhibitors. In operative management various type of operative procedure may be done, out of which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b65e8070911a49aeadba0c61c7d5e0c9
https://doi.org/10.47552/ijam.v12i3.1917
https://doi.org/10.47552/ijam.v12i3.1917